AndroGel Cost in Rhode Island 2026: Cash Price, Insurance, Medicaid, and Compounded Alternatives

What Does AndroGel Actually Cost in Rhode Island in 2026?

The retail cash price for a 30-day supply of AndroGel 1.62% in Rhode Island sits at approximately $510 per month in 2026. That figure reflects AbbVie's manufacturer list price and is consistent across major Rhode Island retail chains. Patients paying without insurance assistance will find little variation between CVS, Walgreens, and independent pharmacies statewide.

Why the List Price Is So High

AndroGel remains under AbbVie's branded pricing despite generic testosterone gel products entering the market after 2015 FDA label for AndroGel 1.62%, NDA 021463. Brand loyalty, patient inertia, and formulary positioning all contribute. The FDA approved the original AndroGel 1% formulation in 2000, with the 1.62% version following in 2011, and AbbVie has maintained list-price escalation on both FDA drug approval history.

Generic Testosterone Gel as a Lower-Cost Brand Alternative

Generic 1.62% testosterone gel (authorized generics from Perrigo and others) is available at Rhode Island pharmacies for $80 to $160 per month depending on the dispensing pharmacy and any applied GoodRx-style coupon. These generics are bioequivalent to AndroGel and carry the same FDA-approved labeling FDA Orange Book entry for testosterone gel. Clinically, switching from brand AndroGel to a bioequivalent generic does not require a laboratory recheck if the patient had stable levels on the brand, though many clinicians draw a serum total testosterone 14 days after any switch.

Compounded Testosterone Gel: $120 Per Month

Compounded testosterone gel produced by a licensed 503A pharmacy in Rhode Island runs approximately $120 per month. That price covers a 30-day supply of testosterone gel at concentrations typically ranging from 1% to 10%, prepared to a prescriber's specifications. Compounded products are not FDA-approved, but the Active Pharmaceutical Ingredient (API) used must meet USP standards FDA 503A compounding guidance. The $390 monthly difference between brand AndroGel and a quality compounded gel is the central financial argument for the compounded route in uninsured Rhode Island patients.

Does Rhode Island Medicaid Cover AndroGel?

Rhode Island Medicaid (RIte Care and Rhody Health Options) covers AndroGel and generic testosterone gel for male hypogonadism, but prior authorization (PA) is required. Without an approved PA, the pharmacy claim will reject. The PA process typically demands a diagnosis of hypogonadism (ICD-10 E29.1 or E23.0), two morning serum total testosterone values below 300 ng/dL drawn on separate days, and documentation that a clinical syndrome of hypogonadism is present.

What the Endocrine Society Says About Diagnosis

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism states: "We recommend against making a diagnosis of androgen deficiency in men with acute or subacute illness and recommend confirming a low serum testosterone concentration by repeating the measurement." Endocrine Society CPG, 2018, Bhasin et al.. Rhode Island Medicaid PA criteria align closely with this guideline requirement for two separate low testosterone readings before approving testosterone replacement therapy.

How to Submit a PA for Rhode Island Medicaid

The prescribing clinician submits the PA through Rhode Island's Kepro system or the Neighborhood Health Plan of Rhode Island portal, depending on which managed care organization (MCO) manages the patient's plan. Processing typically takes 3 to 5 business days for standard review and 24 hours for expedited review when clinical urgency is documented. Approval is generally granted for 12 months and requires annual renewal with lab evidence of continued hypogonadism.

What Happens If the PA Is Denied?

A first-level internal appeal and then a state fair hearing are both available to the patient. Clinicians should attach the two qualifying testosterone values, documentation of symptom burden (low libido, fatigue, reduced bone mineral density), and any relevant pituitary imaging if a secondary cause is suspected NIH clinical overview of hypogonadism. Denied PAs are often overturned when the clinical record is complete.

Which Commercial Insurance Plans in Rhode Island Cover AndroGel?

Most commercial plans sold through the Rhode Island Health Benefits Exchange (HealthSource RI) place testosterone gel products on Tier 3 or Tier 4 of their formulary. At Tier 3, copays run $60 to $120 per 30-day supply. At Tier 4, costs can reach $150 to $250 per fill before the deductible is met.

BCBSRI, Neighborhood Health Plan, and Tufts Health

Blue Cross Blue Shield of Rhode Island (BCBSRI) covers generic testosterone gel on its standard formulary at Tier 3 with PA. Neighborhood Health Plan of Rhode Island mirrors the Medicaid PA requirements for its commercial members. Tufts Health Together (the MA/RI dual-eligible plan) covers testosterone gel for diagnosed hypogonadism with PA. Patients should verify the specific tier placement of AndroGel 1.62% versus generic testosterone gel because substituting the generic could reduce the copay by $40 to $80 per month on most Rhode Island commercial plans.

Step-Therapy Requirements

Several RI commercial plans require a patient to try and fail generic testosterone gel before approving brand AndroGel. This step-therapy protocol is clinically reasonable because the generics are bioequivalent. If a patient has already tried the generic and experienced application-site reactions or subtherapeutic levels at standard dosing, the prescriber can document this to bypass the step-therapy requirement FDA bioequivalence standards for topical testosterone.

The AbbVie Savings Card and myAbbVie Assist Program

AbbVie offers two distinct programs, and Rhode Island patients frequently confuse them.

The Commercial Copay Card

The AbbVie copay savings card for AndroGel reduces the out-of-pocket cost to as low as $0 per month for commercially insured patients. Eligibility requires private insurance (not Medicare or Medicaid) and a valid AndroGel prescription. The card is applied at the pharmacy counter and covers the difference between the plan's cost-sharing and the cap amount. Patients can enroll at AbbVie's AndroGel savings page or ask their RI pharmacy technician to apply the card during dispensing AbbVie program enrollment.

myAbbVie Assist for Uninsured or Underinsured Patients

MyAbbVie Assist is AbbVie's patient assistance program (PAP) for uninsured or underinsured Rhode Island residents who do not qualify for Medicaid. Income limits apply (generally at or below 400% of the federal poverty level). Approved patients receive AndroGel at no cost, shipped directly to their prescriber's office or home address. The application takes 2 to 4 weeks, so clinicians should bridge patients with a compounded testosterone gel or a 30-day generic supply while the PAP processes.

Is Compounded Testosterone Gel Legal in Rhode Island?

Yes. Compounded testosterone gel is legal in Rhode Island when prepared by a licensed 503A pharmacy (a traditional compounding pharmacy operating under state pharmacy board oversight). Rhode Island's Board of Pharmacy licenses compounding pharmacies under the federal Drug Quality and Security Act (DQSA) framework FDA 503A overview. A valid prescription from a licensed Rhode Island prescriber is required.

503A vs. 503B: What Rhode Island Patients Need to Know

A 503A pharmacy compounds for individual patients under a specific prescription. A 503B outsourcing facility produces larger batches and must register with the FDA. Rhode Island patients receiving compounded testosterone gel from a local compounding pharmacy are likely receiving a 503A product. Both routes are legal; however, 503B facilities undergo more frequent FDA inspection and carry slightly higher confidence in sterility and potency testing FDA 503B outsourcing facilities list.

Potency and Purity Considerations

A 2013 study published in JAMA Internal Medicine found that compounded testosterone preparations varied in potency from labeled concentration by up to 50% in some samples JAMA Intern Med, Gudeman et al., 2013. Rhode Island patients using compounded testosterone gel should have serum total testosterone checked 14 days after starting or changing dose, consistent with Endocrine Society monitoring guidance Endocrine Society CPG. Choose a compounding pharmacy that provides a Certificate of Analysis (COA) with each batch.

Can You Get an AndroGel Prescription via Telehealth in Rhode Island?

Telehealth prescribing of testosterone is legal in Rhode Island. A prescriber licensed in Rhode Island can evaluate a patient via synchronous audio-video visit, review qualifying laboratory results, and issue a new or refill prescription for AndroGel or generic testosterone gel. The Rhode Island Department of Health permits telehealth under the same standard of care as in-person visits for Schedule III controlled substances, which includes testosterone RI DOH telehealth regulations.

What a Telehealth Visit for Testosterone Requires in Rhode Island

The prescriber must review at least two morning serum total testosterone values below the laboratory's reference range (typically <300 ng/dL), document a clinical syndrome consistent with hypogonadism, and rule out reversible causes. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels help distinguish primary from secondary hypogonadism NIH, endocrine testing review. Labs can be drawn at any Quest Diagnostics or LabCorp location in Rhode Island before the telehealth visit.

Ryan Haight Act and DEA Telemedicine Rules

Testosterone is a Schedule III controlled substance. Under the DEA's 2024 proposed telemedicine rules for controlled substances, prescribers must either conduct an in-person evaluation at least once or operate under a special registration for telemedicine prescribing of Schedule III substances DEA telemedicine rules, Federal Register. Rhode Island-based telehealth platforms offering testosterone should be asked directly whether they comply with current DEA telemedicine prescribing requirements.

The Clinical Evidence Base for Testosterone Gel Therapy

Understanding the clinical rationale behind testosterone gel prescribing helps patients engage more effectively with their prescribers and insurers.

The Testosterone Trials (T-Trials)

The Testosterone Trials (T-Trials) represent the most rigorous evaluation of testosterone therapy in older men with confirmed hypogonadism. The T-Trials enrolled 788 men aged 65 and older with total testosterone below 275 ng/dL and randomized them to testosterone gel (AndroGel 1%) or placebo for 12 months Snyder PJ et al., NEJM, 2016, N=788. Sexual function, physical function, and vitality outcomes all showed statistically significant improvements in the testosterone arm (P<0.05 for sexual function domain). These data form part of the clinical foundation that insurers and Medicaid programs use when evaluating PA criteria.

Endocrine Society Dosing and Monitoring Targets

The Endocrine Society 2018 guideline recommends maintaining serum total testosterone in the mid-normal range (400 to 700 ng/dL) during replacement therapy Bhasin S et al., J Clin Endocrinol Metab, 2018. AndroGel 1.62% is typically started at 40.5 mg (two pump actuations) applied once daily to the shoulders or upper arms. Dose titration to 20.25 mg or 81 mg is guided by a serum total testosterone measured 14 days after initiation or any dose change, drawn 2 to 8 hours after application.

Hematocrit Monitoring

Testosterone gel raises erythropoiesis. The Endocrine Society guideline specifies checking hematocrit at baseline, at 3 months, and annually thereafter. If hematocrit exceeds 54%, the dose should be reduced or therapy held Endocrine Society CPG, 2018. Rhode Island prescribers ordering testosterone via telehealth should have a clear protocol for routing hematocrit results and acting on out-of-range values NIH, testosterone therapy safety review.

Head-to-Head Cost Comparison: All Rhode Island Options in 2026

The table below organizes the full range of testosterone gel options available to Rhode Island patients by monthly out-of-pocket cost.

| Option | Monthly Cost (RI, 2026) | Requires PA? | Notes | |---|---|---|---| | Brand AndroGel 1.62% (cash) | ~$510 | No | AbbVie list price | | Generic testosterone gel 1.62% (cash) | $80 to $160 | No | Bioequivalent; GoodRx applicable | | Brand AndroGel (commercial insurance, Tier 3) | $60 to $120 copay | Often yes | AbbVie copay card may reduce to $0 | | AndroGel (RI Medicaid, approved PA) | $0 to $3.90 | Yes | RIte Care cost-sharing cap | | Compounded testosterone gel 503A (cash) | ~$120 | No | Not FDA-approved; COA recommended | | AbbVie myAbbVie Assist (uninsured) | $0 | No | Income-based; 2 to 4 week processing | | Telehealth + generic gel | $80 to $200 total | Varies | Includes visit fee estimate |

For the median uninsured Rhode Island adult earning above Medicaid thresholds but below the AbbVie PAP limit, a compounded 503A gel at $120 per month or a generic testosterone gel with a GoodRx coupon at $80 to $130 represents the practical lowest-cost path. Patients with commercial insurance should apply the AbbVie copay card before paying any out-of-pocket amount.

Applying GoodRx and Other Discount Programs in Rhode Island

GoodRx coupons work at Rhode Island retail pharmacies for generic testosterone gel but not for brand AndroGel when an insurance claim has already been submitted. The patient must choose one or the other for each fill. Rhode Island pharmacies that accept GoodRx coupons include CVS (all statewide locations), Walgreens, Rite Aid (remaining RI locations), and most independent pharmacies GoodRx pharmacy network. The discount is applied by giving the pharmacy the GoodRx code before the prescription is processed, not after.

Mark Cuban's Cost Plus Drugs platform listed generic testosterone gel 1.62% at $68 for a 30-day supply as of mid-2025, and Rhode Island patients can use Cost Plus Drugs when their pharmacy is in the network or order by mail Cost Plus Drugs pricing. Availability varies; call ahead to confirm stock.

Practical Steps for Rhode Island Patients in 2026

Getting testosterone gel at the lowest possible cost in Rhode Island follows a short decision tree.

First, confirm diagnosis with two morning total testosterone draws at a Rhode Island lab. Total testosterone below 300 ng/dL on two separate occasions, combined with clinical symptoms, meets both Endocrine Society and RI Medicaid threshold criteria Endocrine Society CPG.

Second, identify insurance status. Rhode Island Medicaid patients should ask their prescriber to submit a PA at the time of the initial visit, not after a denial. Commercial insurance patients should request that the prescriber submit a PA and simultaneously enroll in the AbbVie copay card.

Third, uninsured patients should request a 30-day supply of generic testosterone gel (not brand AndroGel) at initial prescribing and apply a GoodRx coupon while the myAbbVie Assist application is pending. The generic performs identically at a fraction of the brand price FDA bioequivalence.

Fourth, patients interested in compounded testosterone gel should ask their Rhode Island prescriber to send the prescription to a licensed 503A compounding pharmacy that provides batch COAs. Request the COA for each fill and report any symptoms of under- or over-dosing at the 14-day follow-up lab draw.

Monitor serum total testosterone 14 days after starting, hematocrit at 3 months, and PSA at 3 to 6 months per Endocrine Society guidance, regardless of which testosterone formulation or product type is used Endocrine Society CPG, 2018, Bhasin et al..